Lupus Foundation of America1d
New Study Finds Racial and Gender-Specific Approaches May Boost Black Participation in Lupus Clinical Trials
In a new study published in Lupus Science & Medicine, researchers assessed clinical trial perceptions among a predominantly Black cohort of participants with systemic lupus erythematosus (SLE).
Lupus Foundation of America2d
Allogene Therapeutics’ ALLO-329 Received FDA IND Clearance for Autoimmune Disease Trial
The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene ...
Lupus Foundation of America13d
New Study Identifies Predictors of Successful Glucocorticoid Discontinuation in Systemic Lupus Erythematosus Treatment
A new study found that low or absent disease activity, hydroxychloroquine (HCQ) use, and gradual reduction of GC dosing can ...
Lupus Foundation of America11d
Investigator-initiated Study of CNTY-101, for People with Autoimmune Diseases, Including Systemic Lupus Erythematosus and Lupus Nephritis Announced
An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of B-cell mediated autoimmune diseases, including systemic lupus erythematosus ...
Lupus Foundation of America6d
2025 Portland Lupus & You Empowerment Conference
Serving north, central and west Texas, including Dallas/Fort Worth, San Antonio, Austin, El Paso, Lubbock, and surrounding areas Join us for the 2025 Portland Lupus & You Empowerment Conference! Lupus ...
Lupus Foundation of America21d
UPDATE: Phase 1 Trial Begins for Investigational Therapy, CB-010, for Lupus Nephritis Treatment
The Phase 1 GALLOP study evaluating the investigational therapy, CB-010, for treatment of lupus nephritis has launched.